Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
AssigneeU.S. Bioscience, Inc.
InventorHerbert A. Blough
Life of this patent
Estimating the term…
Abstract
Compositions and methods are disclosed which utilize the broad spectrum antiviral activity of PALA. This compound and its pharmaceutically acceptable analogs possess potent activity while displaying minimal toxicity and, therefore, are characterized by a relatively high therapeutic index. Compositions optionally containing other therapeutic agents, such as other antiviral agents, are also disclosed and are found to possess synergistic and/or additive antiviral activity.
Claims13
A method of treating viral infection caused by an RNA virus selected from the group consisting of flaviviruses, bunyaviruses, Hantaan and filoviruses which comprises administering to a mammal in need of antiviral therapy an effective amount of N-(phosphonoacetyl)-L-aspartic acid or a pharmaceutically acceptable analog thereof.
A method of treating viral infection caused by an RNA virus selected from the group consisting of yellow fever, sandfly fever, Rift Valley fever, Dengue virus 1-4, Coxsackie, measles, respiratory syncytial, parainfluenza and influenza A (H.sub.2 N.sub.2 and H.sub.3 N.sub.2) viruses which comprises administering to a mammal in need of antiviral therapy an effective amount of N-(phosphonoacetyl)-L-aspartic acid or a pharmaceutically acceptable analog thereof.
A method of treating viral infection caused by a DNA herpes virus which comprises administering to a mammal in need of antiviral therapy an effective amount of N-(phosphonoacetyl)-L-aspartic acid or a pharmaceutically acceptable analog thereof.
A method of treating disease caused by hepatitis C virus which comprises administering to a mammal in need of such therapy, an effective antiviral amount of N-(phosphonoacetyl)-L-aspartic acid or a pharmaceutically acceptable analog thereof.
A method of treating disease caused by hepatitis B virus which comprises administering to a mammal in need of such therapy an effective antiviral amount of N-(phosphonoacetyl)-L-aspartic acid or a pharmaceutically acceptable analog thereof.
A method of in which treating vital infection caused by an opportunistic viral infection, secondary to HIV-1 or HIV-2, chemotherapy or other causes of immunosuppression which comprises administering to a mammal in need of antiviral therapy an effective amount of N-(phosphonoacetyl)-L-aspartic acid or a pharmaceutically acceptable analog thereof.
Dependencies are inferred from the claim text.